Linus

Quick links to important sections

Linus

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Linus

Quick Facts

Property Description
Active ingredient Dutasteride (INN)
Form Oral soft gelatin capsule, liquid-filled
Pharmacological class 5α-reductase inhibitor (Dual inhibitor)
Origin Synthetic 4-azasteroid compound
Status Prescription-only (Rx)

What is Linus and Its Pharmacological Identity?

Linus is a prescription-only synthetic medication whose active component is Dutasteride (INN), belonging to the specialized class of dual 5α-reductase inhibitors (5-ARIs). This compound is recognized for its hormonal modulating capability, which is a defining feature of its pharmacological profile.

Dutasteride is specifically classified as a dual inhibitor because it targets and blocks both the Type 1 and Type 2 isoenzymes of the 5α-reductase enzyme. This enzyme is essential for the internal conversion of testosterone into the potent androgen dihydrotestosterone (DHT). This mechanism provides significant systemic DHT suppression, which is the cornerstone of its therapeutic application in conditions relevant to adult males.


Form and High-Level Composition of Linus

Linus is prepared as an oral soft gelatin capsule, a specialized dosage form chosen to optimize the drug’s physical characteristics. Each capsule contains the active ingredient Dutasteride dissolved within a liquid base that is formulated to enhance its bioavailability.

This liquid-filled capsule preparation is a key distinguishing feature, necessary because the Dutasteride molecule is highly lipophilic and poorly soluble in water. This design is intended to ensure the body can properly absorb the required amount of the synthetic compound to achieve its intended systemic effect.


General Therapeutic Purpose of Dutasteride

The general therapeutic purpose of Linus is to modulate the effect of androgens by suppressing the production of DHT. This suppression is the primary mechanism of action, as DHT is the primary hormonal driver behind the progressive growth of the prostate gland and the gradual thinning of hair follicles associated with androgenetic alopecia. By limiting the hormonal stimulation of these tissues, the medication provides a long-term approach to counteracting these androgen-dependent physiological processes.

Regulatory References

  1. NIH: StatPearls

What side effects are possible with Linus?

The official safety profile for Linus, which contains Dutasteride, is characterized by adverse reactions grouped according to their incidence and effect on specific physiological systems. This information is derived exclusively from government regulatory documents, such as the FDA and EMA.

Adverse Reaction Scope

Category Description / Entity
Common (ge 1/100 to <1/10) Impotence, Decreased libido, Ejaculation disorders, Breast disorders (gynecomastia, tenderness).
Uncommon (ge 1/1,000 to <1/100) Dizziness.
Not Known (Post-marketing) Hypersensitivity reactions (e.g., angioedema, serious skin reactions), Depressed mood, Testicular pain, Testicular swelling, Male breast cancer, Cardiac failure.

The Reproductive System and Breast Disorders are the most frequently affected systems. Importantly, sexual adverse reactions and breast disorders are most often reported during the first year of treatment and generally decrease with continued, long-term use.

Documented Safety Constraints

Official labeling includes explicit warnings regarding serious risks and specific limitations:

  • High-Grade Prostate Cancer: There is a documented association with an increased risk of high-grade prostate cancer (Gleason score 8–10) in men.
  • PSA Monitoring: Dutasteride reduces serum Prostate-Specific Antigen (PSA) levels, requiring a new baseline to be established and careful evaluation of any confirmed increase in PSA from the lowest value.
  • Pregnant Women: The medication is absolutely contraindicated for use in women and must not be handled by those who are or may become pregnant due to the risk of absorption through the skin and potential for causing birth defects in a male fetus.
  • Capsule Integrity: The capsule must be swallowed whole and not opened, as contact with the contents may result in irritation. Men taking this medication should not donate blood for at least six months after the last dose.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation notes that no unique symptom profile has been identified following acute Dutasteride overdose; clinical trials involving high doses did not report significant adverse events beyond those expected at therapeutic levels. Management is defined by a standard protocol, as no specific antidote is known for Dutasteride. Treatment must be strictly symptomatic and supportive.

When to Seek Urgent Medical Attention

Regulators mandate that immediate medical attention must be sought for severe, life-threatening manifestations, which include:

  • Signs of a severe allergic reaction, such as angioedema, swelling of the face, tongue, or throat, or difficulty breathing or swallowing.
  • Systemic distress indicated by collapse, seizure, or being unable to be awakened.

In these severe cases, emergency services (e.g., 911) or the Poison Help line should be contacted immediately. Given the drug’s long half-life, the patient’s clinical status may require continuous hospital monitoring to manage symptoms. Furthermore, due to the drug’s extensive metabolism, regulatory documents advise that caution must be exercised, and no dosage recommendation can be made, for patients with severe hepatic impairment.

Therapeutic Uses of Linus

What Linus Treats: Main Uses and Benefits

Linus is commonly used for managing conditions characterized by chronic and episodic manifestations, primarily those involving constipation and associated discomfort. It is indicated for the symptomatic treatment of specific gastrointestinal disorders in adults, including conditions characterized by periods of heightened symptoms such as persistent constipation and intestinal discomfort.

The medication is relevant when supportive symptom management is appropriate across conditions involving episodic or fluctuating manifestations. It helps address symptom clusters that create noticeable physiological strain, assisting with symptoms related to physical discomfort such as abdominal pain, bloating, and difficulty in passing stools. Linus provides supportive relief when symptoms intensify and interfere with daily comfort.

“It contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Supports patients with symptoms related to straining and constipation

Regulatory References

  1. European Medicines Agency overview

Eligibility and Restrictions for Use

Official Eligibility Profile

Linus (Dutasteride) is intended strictly for use in adult men. Regulatory documents universally define severe population exclusions based on sex, age, and pre-existing conditions.

Category Regulatory Status
Populations for whom use is allowed Adult men (typically age 18 and older)
Populations for whom use is contraindicated Females (all women), including Pregnancy. Pediatric patients (children and adolescents). Patients with known, clinically significant hypersensitivity to dutasteride, other 5α-reductase inhibitors, or any component of the capsule.
Age-related eligibility rules Use in the pediatric population is contraindicated, as safety and efficacy have not been established. No dose adjustment is required for older adult men.
Condition-specific eligibility Severe hepatic disease is a contraindication in some regions. Caution is advised for use in all patients with liver impairment. No dose adjustment is necessary for patients with renal impairment.
Eligibility-related restrictions Women who are pregnant or may become pregnant must not handle the capsules due to the risk of transdermal absorption. Men taking this medicine must not donate blood until at least six months following the last dose.

Connection to the overall eligibility profile: The official profile is defined by absolute contraindications that prohibit its use in women and children. Use is restricted exclusively to men, and is conditional upon being assessed for other urological diseases prior to initiation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Linus (Dutasteride) is defined by documented pharmacokinetic interactions that specifically affect its clearance from the body. The primary constraint involves the potential for elevated drug levels when co-administered with certain medicines.

Metabolic Inhibition and Exposure

The major interaction documented in regulatory labels involves co-administered substances that inhibit the cytochrome P450 isoenzymes CYP3A4 and CYP3A5. Dutasteride is extensively metabolized by these enzymes, and their inhibition leads to a reduced clearance of the drug.

Regulatory documents specifically identify potent and moderate inhibitors such as Ketoconazole, Ritonavir, Verapamil, and Diltiazem as agents that may significantly increase Dutasteride plasma concentrations. This reduced clearance may result in up to 1.8 times greater systemic exposure, and caution is similarly advised for other CYP3A4 inhibitors, including Cimetidine and Ciprofloxacin.

Administration and Interaction Cautions

Category Official Regulatory Statement
Food Timing The product can be taken with or without food. Food reduces the maximum concentration but does not significantly affect overall bioavailability.
Population Risk Administration should be cautious in patients with hepatic impairment (liver disease), as impaired metabolism is expected to result in higher systemic exposure.
Herbal Products Official regulatory guidance advises awareness regarding potential interactions with herbal products, such as St. John's Wort, which may influence metabolic enzyme activity.

The interaction profile is structured around the primary goal of mitigating the risk of elevated plasma concentrations arising from impaired metabolic clearance.

Mechanism of Action

How Linus Works: Mechanism of Action

Dual Enzyme Inhibition of 5alpha-Reductase

Linus's mechanism centers on its role as a dual inhibitor that forms a stable, irreversible complex with both the Type 1 and Type 2 isoenzymes of the 5alpha-reductase enzyme. This molecular action shuts down the enzymatic conversion of the pro-hormone Testosterone into the more biologically potent androgen, Dihydrotestosterone (DHT).


High-Degree Hormonal Pathway Modulation

The sustained inhibition of 5alpha-reductase leads to a significant and sustained suppression of DHT levels in the body, typically reducing circulating concentrations by over 90%. This systemic modulation reduces the magnitude of androgenic stimulation on androgen-sensitive tissues, establishing the hormonal environment required for downstream physiological effects.


Tissue Volume Adjustment via Androgen Signal Reduction

By limiting the availability of DHT, the mechanism reduces the primary growth signal required by target cells. This action diminishes the drive for cell proliferation and promotes programmed cell death (apoptosis). This cascade mediates a process of cell death and decreased proliferation, leading to the adjustment of prostate gland volume and the diminishment of androgen-induced hair follicle atrophy.

Dosage and Administration Information

Instruction Map: How to use Linus — Administration Guidelines

Administration Scope

Route of administration: Oral

Dosing schedule: 0.5 mg once daily (standard dose).

Timing in relation to meals (if applicable): May be taken with or without food.

Preparation requirements (if applicable): None.

Age-group administration rules: Older Adults require no dose adjustment. No dose adjustment is necessary for renal impairment. Caution is advised for hepatic impairment patients, for whom specific dosage recommendations are not established.

Missed-dose rules: If a dose is missed, the patient should not take a double dose. The next scheduled dose should be taken the following day at the usual time.

Special procedural conditions: The medication is designated for long-term continuous use.


Instruction Classifications (High-Level)

Administration method type: Oral (Soft Gelatin Capsule)

Frequency pattern: Daily

Use-context constraints: Sustained, non-cyclic maintenance therapy.


Resulting Procedural Structure

Step sequence:

  • Ingest the 0.5 mg soft gelatin capsule by mouth.
  • Swallow the capsule whole with water; do not chew, open, or crush the capsule, as this may cause irritation.
  • Adhere strictly to the once-daily schedule, regardless of food intake.

Connection to the Overall Use Protocol

The instructions define a standardized protocol of use that requires consistent, long-term, once-daily oral administration of the fixed 0.5 mg dose. This routine is intended to establish and maintain steady drug levels over an extended period, which is essential for the medication's intended physiological effect, with specific restrictions placed on altering the integrity of the specialized capsule.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Linus

The research concerning Linus (Dutasteride) documents the structure of the research base, which includes numerous randomized controlled trials (RCTs), systematic reviews, and long-term observation studies. These studies were conducted during periods of increased symptom activity and were designed to provide context on how outcomes related to systemic or functional imbalance change over defined time intervals.


Evidence for use in Symptomatic Benign Prostatic Hyperplasia (BPH)

Research for BPH primarily involves large-scale, multi-center RCTs used in research exploring how symptoms change over time. The main outcomes monitored included patient-reported scores and objective physical measures like total prostate volume (TPV) and maximum urine flow rate (Q max). Researchers monitored the incidence of major BPH-related clinical events, such as surgery or acute urinary retention (AUR), as a primary outcome across the long-term observation period (up to four years).

Findings describe patterns observed in the studies related to changes in patient symptom scores and quality of life indices. The data documented measurements of change in prostate size and changes in urine flow rates in the studied groups. The measurement of prostate-specific antigen (PSA) levels in the blood was reported to be reduced in the treatment groups, which necessitates careful clinical interpretation when screening for prostate cancer, as certainty remains low about the long-term impact on the detection of high-grade cancers.


Evidence for use in Male Androgenetic Alopecia (AGA)

Research for male AGA consists mainly of RCTs that examine outcomes related to changes in hair growth in adult men with hair thinning. The primary outcomes involved objective measurements of hair density, focusing on the total number of hairs within a standardized target area on the scalp, and subjective investigator assessments of hair appearance.

Trials exploring short-term changes reported how hair density measurements evolved in the observed populations, with some studies describing measurements of change in hair count and thickness over periods as short as 24 weeks. A key limitation is that many high-quality, placebo-controlled RCTs are relatively short-term, and data for certain groups remain insufficient regarding long-term outcomes for hair loss in all regions of the scalp (e.g., the frontal area).

Frequently Asked Questions (FAQ)

Common questions about Linus (FAQ)


Q: How does the body process Linus after it is taken?

The official product information describes how Linus is extensively processed, or metabolized, by the liver. Due to this process, the medication has a very long presence in the body, with a half-life of approximately four to five weeks. Most of the drug is eliminated through the feces as various breakdown products.


Q: How quickly can someone expect Linus to start working?

Studies and official information indicate that Linus is intended for long-term, sustained therapy. Because the drug works by gradually suppressing hormone levels, it may take several months of continuous use before initial benefits or observable physical changes occur.


Q: Can Linus affect my ability to drive or operate machinery?

The regulatory label lists dizziness as an uncommon side effect of Linus. Official information suggests that if dizziness occurs, activities requiring concentration, such as driving or operating machinery, may need to be approached with caution.


Q: Is it normal to feel tired or dizzy after starting Linus?

According to official regulatory documents, dizziness is classified as an uncommon side effect. While tiredness or fatigue are not among the most frequently reported adverse reactions, they have been reported in post-marketing surveillance or rare incidence categories.


Q: Can taking Linus long-term cause liver or kidney problems?

Regulatory documents indicate that the drug is processed primarily by the liver. Official labeling notes that patients with pre-existing liver impairment are expected to use the medication with caution. However, the label does not specifically list causing long-term kidney or liver damage as a common or serious adverse reaction in otherwise healthy individuals.


Q: Can I take Linus with my regular vitamins or herbal supplements?

Official documents require that all prescription medicines, nonprescription products, nutritional supplements, and herbal remedies being taken are reported to a healthcare provider. Regulatory documents specifically note the potential for interactions with herbal products like St. John’s Wort, but do not explicitly list significant interactions with common vitamins.


Q: What is the success rate of Linus in clinical trials?

Regulatory documents and studies typically do not define a single overall “success rate” percentage. Instead, research documents the outcomes by tracking measurable changes, such as adjustments in prostate volume, improvements in urine flow rate, or changes in hair density measurements over the course of treatment.


Q: Is it safe to use Linus during pregnancy or while breastfeeding?

Linus is strictly contraindicated for use by all women. This is particularly important during pregnancy, where the drug poses a risk of causing birth defects in a male fetus. The regulatory label also states that information is not available regarding the drug's presence in human breast milk or its effects on a breastfed infant.


Q: What is the purpose of the black box warning (if any) associated with Linus?

The US prescribing information contains a Boxed Warning, which is a key caution from the regulatory agency. This warning addresses a documented association with an increased risk of high-grade prostate cancer (Gleason score 8–10) in men who take the medication.


Q: Is there any research evidence on the use of Linus in specific populations?

Regulatory documents specify findings related to certain patient groups. For example, official information indicates that no dose adjustment is required for older adult men or for patients with renal impairment (kidney issues). The medication's safety and efficacy have not been established in the pediatric population.


Q: Is it safe to drink alcohol while taking Linus?

There is no specific, major regulatory warning of a direct interaction between Linus (when used as monotherapy) and alcohol listed in the official labeling. The lack of a specific warning does not eliminate all general health concerns related to alcohol consumption while taking any prescription medication.


Q: Does Linus interact with common over-the-counter pain relievers?

The official interaction profile primarily focuses on substances that can inhibit specific liver enzymes (CYP3A4/5), such as the over-the-counter stomach acid reducer Cimetidine. Most common over-the-counter pain relievers are not listed as major drug interaction concerns in regulatory documents.


Q: Are the side effects of Linus the same for all age groups?

Official documents note that no geriatric-specific problems have been identified that would limit the usefulness of the medication in older adults. However, the general adverse reaction tables do not specifically break down the incidence or severity of side effects by all distinct age groups.


Q: Does Linus cause weight gain or weight loss?

Weight gain has been reported as a rare adverse reaction in clinical experience and post-marketing surveillance. Official labeling also documents swelling associated with fluid retention, which can be related to weight changes.


Q: Is Linus considered a controlled substance or addictive?

Linus is classified as a prescription-only (Rx) medication. It is not listed as a scheduled controlled substance by the U.S. Drug Enforcement Administration or equivalent government agencies.


Q: What phase of clinical trials was Linus studied in before approval?

Official documents referencing the development of Linus mention research studies conducted under Phase II and Phase III clinical trial protocols. These trials were carried out to support the medication's authorized indications and safety profile.


Q: Does Linus contain any common allergens, such as lactose or gluten?

The capsule's inactive ingredients include gelatin, glycerin, and other compounds. Common allergens such as lactose or gluten are not listed among the inactive ingredients in the official prescribing information for Linus.


Q: Is there a generic version of Linus available?

The active ingredient in Linus is Dutasteride. The U.S. Food and Drug Administration (FDA) has approved generic versions of Dutasteride, which may be available depending on local market conditions and pharmacy stock.


Q: What should be done if someone accidentally takes too much Linus?

The official prescribing information indicates that for an overdose, emergency medical attention is needed immediately. Treatment for an overdose is typically supportive, as there is no specific antidote known for this medication.

How should Linus be stored and disposed of?

Linus (Dutasteride) capsules must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F), kept in their original, tightly closed container, protected from excess heat and moisture.

Mandatory Handling Rules: Do not chew or open the capsules; they must be swallowed whole. Due to the risk of dermal absorption, women who are pregnant or may become pregnant must not handle the capsules, and contact areas must be washed immediately with soap and water.

All unused medication must be kept out of the reach of children. For disposal, men taking Linus must not donate blood until at least 6 months after the last dose. Unused or expired capsules should be disposed of according to local pharmaceutical regulations or through a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Linus found in:

A-Z Index: